Depo-Provera lawsuit overview:
- Who: Pfizer and plaintiffs in the Depo-Provera multidistrict litigation reached an agreement in principle to resolve claims.
- Why: Plaintiffs claim Pfizer failed to warn consumers that Depo-Provera may increase the risk of developing meningioma brain tumors.
- Where: The multidistrict litigation is pending in Florida federal court.
- How to get help: If you or a loved one used Depo-Provera continuously for at least one year and were later diagnosed with a meningioma that required surgical removal, you may qualify to join the Depo-Provera lawsuit.
Pfizer reached an agreement in principle to resolve thousands of lawsuits alleging the company failed to warn consumers about an alleged link between its Depo-Provera contraceptive injection and meningioma brain tumors.
According to a court order, the parties informed U.S. District Judge M. Casey Rodgers that they had reached a global agreement that would allow eligible plaintiffs with pending cases in the multidistrict litigation to resolve their claims.
Following the announcement, Judge Rodgers vacated deadlines in the first bellwether case, which had been scheduled for trial in December 2026. The court also postponed a hearing concerning the admissibility of plaintiffs’ causation evidence from June 24 to July 27.
The terms of the Pfizer Depo-Provera agreement have not been disclosed.
A Pfizer spokesperson said, “The company has reached an agreement in principle with plaintiff leadership in the Depo-Provera MDL that provides an opportunity for MDL plaintiffs to resolve their claims,” as reported by Law360.
Pfizer emphasized that the agreement contains no admission of liability or wrongdoing and does not affect cases pending in state courts. The company also said it intends to continue defending any remaining claims and maintains that Depo-Provera is safe and effective.
Plaintiffs allege Depo-Provera increased brain tumor risk
The Depo-Provera lawsuits claim medical and scientific studies linking the contraceptive injection to an increased risk of meningiomas have existed for years. According to the plaintiffs, Pfizer failed to adequately study or warn consumers about the risk.
Meningiomas are tumors that develop in the membranes surrounding the brain and spinal cord. Although typically noncancerous and slow-growing, they can cause serious symptoms, including headaches, seizures and vision problems.
The litigation cites a 2025 study published in JAMA Neurology that examined data from more than 61 million women in the United States. Researchers reportedly found a 2.43-fold increased risk of meningioma among women who used injectable depot medroxyprogesterone acetate for four or more years or who began treatment after the age of 31.
The study did not identify a similar increased risk for other contraceptive products.
Plaintiffs’ co-lead counsel Christopher Seeger said the agreement represents an opportunity to provide relief for women diagnosed with meningiomas after using Depo-Provera.
The Judicial Panel on Multidistrict Litigation consolidated more than 70 Depo-Provera lawsuits into the federal proceeding in February 2025. Since then, the litigation has expanded significantly, with more than 3,400 lawsuits now pending.
What do you think about this proposed Depo-Provera litigation resolution? Let us know in the comments.
The plaintiffs are represented by Christopher Seeger of Seeger Weiss LLP, Bryan Aylstock of Aylstock Witkin Kreis & Overholtz PLLC, Ellen Relkin of Weitz & Luxenberg P.C. and Virginia Buchanan of Levin Papantonio Proctor Buchanan O’Brien Barr Mougey P.A.
The Depo-Provera multidistrict litigation is In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation, Case No. 3:25-md-03140, in the U.S. District Court for the Northern District of Florida.
Don’t Miss Out!
Check out our list of Class Action Lawsuits and Class Action Settlements you may qualify to join!
Read About More Class Action Lawsuits & Class Action Settlements:
